Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 3,087 shares, a drop of 82.3% from the August 15th total of 17,431 shares. Based on an average trading volume of 24,723 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are short sold.
Raia Drogasil Price Performance
Shares of RADLY stock traded down $0.08 on Friday, hitting $3.73. The stock had a trading volume of 6,891 shares, compared to its average volume of 32,766. The company has a fifty day moving average price of $3.67 and a two-hundred day moving average price of $4.01. Raia Drogasil has a twelve month low of $3.08 and a twelve month high of $5.34.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.05. The business had revenue of $2.17 billion during the quarter, compared to analysts’ expectations of $2.32 billion. Raia Drogasil had a return on equity of 18.20% and a net margin of 2.97%. On average, equities research analysts forecast that Raia Drogasil will post 0.17 earnings per share for the current year.
About Raia Drogasil
Raia Drogasil, now operating under the brand name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a nationwide network of pharmacies that sells prescription and over-the-counter medicines, personal-care products, cosmetics, health and wellness items, and convenience products.
The company also provides digital shopping and delivery services through its online channels, supporting customers with medication and health-related purchases. Its operations combine physical stores with e-commerce and other healthcare-related services, serving consumers throughout Brazil.
RD Saúde was formed in 2011 through the merger of Drogasil and Droga Raia, two pharmacy chains with roots dating back to the early twentieth century.
See Also
- Five stocks we like better than Raia Drogasil
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
